Quick Facts

• Therapeutic Domain: Acute diarrhea with gas-related symptoms (e.g., cramping, bloating).
• Primary Benefit: Offers support for discomfort associated with excessive intestinal movement and gas retention.

---

Stoperan Plus is a compound formulated to provide symptomatic support for temporary episodes of acute diarrhea when these episodes are accompanied by gas-related discomfort. Its intended use is to help manage symptoms such as abdominal cramping, feeling bloated, and the passing of excessive gas that can occur concurrently with acute diarrheal events.

The compound focuses on aiding the gastrointestinal tract to regain a sense of equilibrium. It supports the reduction of unusually high intestinal movement, which in turn may help reduce the frequency of bowel movements. This effect is intended to contribute to improved management of fluid and electrolyte balance often challenged by diarrheal episodes.

By addressing both the excessive bowel activity and the presence of uncomfortable gas, the treatment aims to offer comprehensive, temporary relief for these specific digestive challenges. It is intended for use in adults and children who meet the specified minimum age criteria.

The therapeutic goal is to help stabilize the digestive process and contribute to a return to normal daily function during an acute, uncomplicated episode.

Eligibility for Stoperan Plus: Official Regulatory Status

Official regulatory documentation establishes strict guidelines regarding the populations eligible and non-eligible to use this Loperamide/Simethicone combination product.

Eligibility Status	Population Criteria
Allowed Use	Adults and adolescents 12 years of age and older for acute diarrhea. Adults 18 years and over for acute Irritable Bowel Syndrome (IBS) diarrhea, only if initially diagnosed by a physician.
Contraindicated	Children under 12 years of age (for the OTC fixed combination) and children under 2 years (absolute Loperamide contraindication).

Absolute Non-Eligibility (Contraindications)

The medicine is officially prohibited for use in patients with:

• Known hypersensitivity to any of its components.
• Acute dysentery, characterized by blood in the stools and high fever.
• Acute ulcerative colitis or pseudomembranous colitis.
• Any condition where inhibition of peristalsis is to be avoided (risk of ileus or toxic megacolon).
• Abdominal pain in the absence of diarrhea.

Restricted or Conditional Use

• Hepatic Impairment: Patients with liver dysfunction must use the medicine with caution, and those with severe impairment require medical supervision.
• Physiological States: Use is not recommended during pregnancy or breastfeeding.
• Acute Symptom Worsening: The medicine must be discontinued immediately if constipation, abdominal distension, or ileus develops.

Interactions with other medicines and products

Official regulatory information for this combination medicine focuses on interaction patterns linked to its two active ingredients: Loperamide and Simethicone.

Pharmacokinetic and Metabolic Interactions

Co-administration with inhibitors of certain drug clearance pathways is officially documented to increase Loperamide plasma concentration. Pharmacokinetic interactions occur with potent P-glycoprotein (P-gp) inhibitors, such as quinidine and ritonavir, which can cause a significant rise in Loperamide systemic exposure. Similarly, regulatory labels document that CYP3A4 inhibitors (e.g., itraconazole) and CYP2C8 inhibitors (e.g., gemfibrozil) can inhibit Loperamide's metabolism, also leading to increased systemic levels.

Loperamide may also affect the plasma concentration of co-administered medicines; for example, it has been shown to reduce the exposure of the anti-HIV drug saquinavir.

Pharmacodynamic and Absorption Interactions

Co-use with other Central Nervous System (CNS) depressants, including alcohol, may result in an officially documented additive effect that increases the risk of drowsiness or dizziness. Furthermore, due to the Simethicone component, a specific timing separation is required for certain co-administered drugs. The regulatory constraint requires thyroid medications, such as levothyroxine, to be administered at least four hours apart from this medicine to prevent reduced absorption of the thyroid hormone.

Interaction-Related Restrictions

Combinations with potent P-gp inhibitors or medicines that prolong the QT interval are formally advised against or considered contraindicated in regulatory labeling due to the heightened potential for serious cardiac adverse effects, especially when Loperamide is used at high doses. Patients with liver disease may experience reduced clearance, making them more susceptible to adverse effects from interacting medicines.

How Stoperan Plus Works

The effect of Stoperan Plus results from two distinct mechanisms that operate on the gastrointestinal tract simultaneously: one neurochemical, and one purely physical.

---

Modulating Gut Motility via Peripheral Opioid Receptors

The primary mechanistic domain of Loperamide involves the agonism at the boldsymbolmu-opioid receptors (mu type) situated within the myenteric plexus of the intestinal wall. Activation of these receptors inhibits the release of excitatory mediators, such as Acetylcholine and Prostaglandins, which signal muscle contraction. This targeted peripheral action significantly slows propulsive peristalsis, thereby increasing the time contents remain in the bowel and facilitating enhanced reabsorption of water and electrolytes.

---

Anti-secretory Action and Fluid Transport Regulation

Loperamide also operates within an anti-secretory mechanistic domain. Beyond its effect on motility, it influences cellular pathways by modulating intracellular components like Calmodulin and specific Calcium channels. This action limits the active secretion of fluids and electrolytes into the bowel lumen. The resulting physiological consequence is a net shift towards fluid reabsorption, which contributes to the consolidation of stool consistency and alters the net fluid component of the intestinal output.

---

Physical Defoaming of Trapped Gastrointestinal Gas

The co-ingredient, Simethicone, functions through a purely physical mechanism as an inert surfactant (antifoaming agent) within the GI lumen. It significantly reduces the surface tension of liquid surrounding small, persistent gas bubbles trapped in mucus. This allows the small bubbles to rapidly coalesce into larger, more mobile pockets of gas, which facilitates their expulsion from the digestive tract.

How to Use Stoperan Plus

The administration of the Loperamide (2 mg) and Simethicone (125 mg) fixed-dose combination product is established for the short-term management of acute diarrhea. The standard protocol involves an oral route of administration using the tablet or caplet form.

---

Labeled Dosing and Frequency

Population	Initial Dose	Subsequent Dose (After Each Loose Stool)	Maximum Dose per 24 Hours
Adults & Adolescents (≥ 12 yrs)	2 tablets (4 mg Loperamide)	1 tablet (2 mg Loperamide)	4 tablets (8 mg Loperamide)
Children (9–11 yrs)	1 tablet (2 mg Loperamide)	1 tablet (2 mg Loperamide)	3 tablets (6 mg Loperamide)
Children (6–8 yrs)	1 tablet (2 mg Loperamide)	1 tablet (2 mg Loperamide)	2 tablets (4 mg Loperamide)

---

Procedural and Time Constraints

The administration is event-driven, meaning a dose is taken only following a loose stool and not on a fixed time schedule. The medicine must be taken with a full (8 oz.) glass of water or clear fluid to support administration. A critical condition for use is the emphasis on continuous fluid and electrolyte replacement to prevent dehydration caused by the underlying condition. The treatment course is limited to a maximum of two days (48 hours); the medication must be discontinued if symptoms resolve sooner or if this time limit is reached. Dosing for children under 12 years is based on age and weight, with children under 6 years generally not recommended for use.

Research Evidence for Stoperan Plus: Overview of Studies

---

Evidence for Use in Acute Diarrhea

Studies have explored the use of Stoperan Plus in individuals experiencing conditions associated with acute or disruptive episodes, specifically sudden, short-term diarrhea. Research examined how this treatment approach was applied in studies examining patient-reported experiences related to physical discomfort.

The findings from these trials describe patterns observed in the studies related to outcomes describing episodic or acute changes. Research highlights changes measured during the study period, and data show patterns related to how patients reported their experience during a temporary physiological imbalance. However, research exploring short-term symptom changes, while providing insight, does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Evidence for Use in Chronic Diarrhea Associated with Underlying Conditions

Research was studied for how Stoperan Plus was used in individuals with conditions involving periods of heightened symptoms, which can be marked by functional limitations. These studies explored the treatment's role in outcomes related to systemic or functional imbalance over longer periods.

Evidence for this application focuses on outcomes reflecting daily functioning or activity level, where the symptoms may vary in intensity. Studies monitored patient-reported outcomes describing perceived discomfort in individuals with periods of heightened symptom activity. However, comparative evidence is lacking, and data for certain groups remain insufficient. While research has explored this application, long-term effects are not fully established.

What is Still Uncertain about Stoperan Plus

This section synthesizes the main evidence gaps and inconsistent findings. Research highlights several areas where more research is needed. Findings were mixed or inconsistent in certain research scenarios, particularly when studies were conducted during periods of increased symptom activity in diverse patient groups. Key research limitation frames include limited information for long-term outcomes, as well as the uncertainty arising from differing evidence quality across various studies. Comparative evidence is lacking to definitively show patterns related to Stoperan Plus against all other available options.

Key Studies & References

1. Loperamide-simethicone combination for the treatment of acute diarrhea: a review of the evidence

Common questions about Stoperan Plus (FAQ)

Q: What is Stoperan Plus and what is it used for?

Stoperan Plus is a medication used to treat sudden (acute) diarrhea associated with abdominal discomfort, such as cramps, gas, and bloating.

It contains two active substances:

• Loperamide hydrochloride: This helps reduce diarrhea by slowing down the movement of the gut, allowing more time for water to be absorbed. This makes the stools firmer and less frequent.
• Simethicone: This works by breaking down gas bubbles in the gut, which helps relieve the painful symptoms associated with gas, such as bloating and cramps.

Q: How should I take Stoperan Plus?

Adults and children over 12 years of age should follow this general guidance, unless a doctor advises otherwise:

1. Initial dose: Take 2 capsules at the start of treatment.
2. Subsequent dose: Take 1 capsule after each episode of loose stool.
3. Maximum dose: Do not take more than 4 capsules in any 24-hour period.

Treatment should generally not exceed 2 days. If diarrhea persists after 2 days of treatment, you should stop taking Stoperan Plus and consult a doctor.

Q: Can Stoperan Plus be used for all types of diarrhea?

No, Stoperan Plus is specifically for acute diarrhea when accompanied by symptoms like abdominal discomfort, cramping, and gas.

It should not be used if your diarrhea is caused by:

• Severe bacterial infection (indicated by high fever or blood in the stool).
• Antibiotic-associated colitis (diarrhea linked to taking antibiotics).
• Severe inflammation of the large intestine (like ulcerative colitis).

If you have any of these conditions, or if you are unsure of the cause of your diarrhea, consult a doctor.

Q: Are there common side effects of Stoperan Plus?

Like all medicines, Stoperan Plus may cause side effects, although not everyone gets them.

Common side effects (may affect up to 1 in 10 people) include:

• Headache
• Nausea
• Altered taste

Uncommon side effects (may affect up to 1 in 100 people) include:

• Dry mouth
• Dizziness, drowsiness
• Constipation, vomiting, upper abdominal pain

If you experience any severe side effects, especially severe abdominal pain, severe constipation, or swelling of the face, throat, or tongue (allergic reaction), stop taking the medicine immediately and seek urgent medical help.

Q: What should I do if I miss a dose of Stoperan Plus?

If you miss a dose, simply wait until the next episode of loose stool and take one capsule. Do not take a double dose to make up for a forgotten dose.

Remember to never exceed the maximum dose of 4 capsules in a 24-hour period.

How to Store and Dispose of Stoperan Plus

Stoperan Plus (Loperamide hydrochloride and Simethicone tablets) must be stored according to official regulatory requirements to maintain product integrity and safety.

Storage Conditions

• Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).
• The tablets must be protected from light.
• Do not use the product if the carton is open or if the individual blister units are torn or opened.

Child Safety and Disposal

• It must be kept out of reach of children. The product is supplied in child-resistant and tamper-evident packaging.
• Official regulatory guidance for disposal indicates no special requirements for discarding unused or expired tablets.